insights_auto
Why is MVIR down 2.15%?
Dive Deeperchevron_right
MVIR:STO
Medivir AB
SEKÂ 1.55
arrow_downward
-2.15%(-0.034) 1D
Oct 7, 5:29:47 PM GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
SEKÂ 1.56
High
SEKÂ 1.58
Low
SEKÂ 1.53
Mkt. cap
967.92M
Avg. vol.
1.71M
Volume
1.17M
52-wk high
SEKÂ 2.88
52-wk low
SEKÂ 0.34
EPS
-SEKÂ 0.37
Shares outstanding
624.18M
No. of employees
6
Open
SEKÂ 1.56
High
SEKÂ 1.58
Low
SEKÂ 1.53
Mkt. cap
967.92M
Avg. vol.
1.71M
Volume
1.17M
52-wk high
SEKÂ 2.88
52-wk low
SEKÂ 0.34
EPS
-SEKÂ 0.37
Shares outstanding
624.18M
No. of employees
6
News stories
From web sources and news partners
BigGo Finance
·
1 hour ago
AI capex surges 116% year-over-year as S&P 500 Q3 earnings poised to rise 27% to record
Sherwood News
·
19 minutes ago
CCCs and desist
TradingView
·
54 minutes ago
15 dividend stocks beating the S&P 500 as markets sit near record highs
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB